PSMA-PET imaging of recurrent prostate cancer
This study examined the use of PSMA-PET, an advanced imaging technique, and how its use might improve outcomes for patients with recurring prostate cancer. PSMA-PET is more sensitive and specific than older imaging methods like CT scans and bone scans, especially for identifying cancer that has come back after initial treatment. However, it’s still unclear if switching to this technology will improve long- term patient outcomes.
The study used a decision-making model to estimate how PSMA-PET might affect patients over time, specifically focusing on those who had completed initial prostate cancer treatment but experienced a return of the disease, known as biochemical recurrent (BCR) prostate cancer.
Data came from existing studies and two hospital databases. Researchers compared three different imaging strategies. They looked at factors like the number of cancer diagnoses, deaths, life expectancy, and quality-adjusted life years, which measure both the length and quality of life.
The PSMA-PET strategy also led to the highest quality-adjusted life years gained, showing it could add meaningful years of life and improve quality.
Interestingly, benefits varied depending on patients’ PSA levels (a marker of cancer recurrence); patients with higher PSA levels gained more life years and had a lower chance of death when PSMA-PET was used. Overall, the study suggests that if PSMA-PET is used first for patients with biochemical recurrent prostate cancer, it could lead to fewer deaths and better quality of life, especially if treatment begins earlier.
This model shows the potential for PSMA-PET to improve long-term outcomes for patients.
JAMA Netw Open. 2024;7(10):e2440591. doi:10.1001/jamanetworkopen.2024.40591
